Mylan Recalls Atorvastatin Calcium Tablets Due to Microbial Contamination
Mylan Pharmaceuticals is recalling specific lots of Atorvastatin Calcium 10 mg tablets due to potential microbial contamination and elevated bioburden.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the identification of objectionable organisms in a pharmaceutical product.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling specific lots of Atorvastatin Calcium Tablets, 10 mg, due to microbial contamination of non-sterile products. The recall is initiated because of the potential for an elevated bioburden with the identification of objectionable organisms.
The affected product is packaged in 90-count and 500-count bottles and is distributed nationwide in the USA and Puerto Rico. The recall covers 1,233,107 bottles across multiple lot numbers and expiration dates ranging from October 2017 to September 2018.
Consumers and healthcare providers should check their medication for the specific NDC codes and lot numbers listed in the official recall notice. If the product matches the recalled lots, it should be returned to the pharmacy or healthcare provider for replacement or refund.
The recalled product
- Product
- Atorvastatin Calcium Tablets, 10 mg*, packaged in a) 90-count bottles (NDC 0378-3950-77); b) 90-count bottles (NDC 0378-3950-09); c) 500-count bottles (NDC 0378-3950-05); d) 500-count bottles (NDC 0378-3950-07), Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 1,233,107
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) 3076141
- 3076142
- Exp 05/18
- 2007223
- Exp 06/18
- 2007335
- Exp 07/18
- 2007336
- Exp 08/18
- 2007446
- 3084691
- Exp 09/18
- 3084692
- Exp 01/18
- b) 3073773
- 2007445
- c) 3076139
- 3076140
- 3076143
- 3076144
Distribution
Part of a larger recall action
This product is one of 4 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · microbial contamination
See all →- CriticalVictory Medical Center Pharmacy Recalls Glutathione Vials Due to Contamination
FDA (Drugs) · 2026-08-19
- HighMedline Medical Convenience Kits Recalled Due to Potential Bacillus Contamination
FDA (Devices) · 2026-07-29
- HighMedline Convenience Kits Recalled Over Bacillus Contamination
FDA (Devices) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15